This document is a publication of a new patent application filed with the USPTO. It describes methods for treating or preventing protein-aggregation diseases through the administration of a sulfatase inhibitor. The application, identified as US20260083700A1, was filed on September 26, 2025, and lists Manuel J. Muñoz, Ángel M. Carrión, and Mercedes M. Pérez-Jiménez as inventors.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in therapeutic approaches for protein-aggregation diseases, which may be relevant for pharmaceutical companies and drug manufacturers involved in research and development in this area. Compliance officers should monitor the progression of this patent application and any granted patents for potential impacts on intellectual property and market exclusivity in the relevant therapeutic space.